Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer.

Clinical colorectal cancer·2026
Same author

Community Safety Needs and Resources and Their Alignment: A Case Study.

Journal of urban health : bulletin of the New York Academy of Medicine·2026
Same author

Podium Abstracts Presented at the 2025 Annual Meeting of the Arthroscopy Association of North America.

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association·2026
Same author

Renal tumors harboring FLCN mutations: Case series from clinical practice.

Human pathology·2026
Same author

Survey Study of Canadian Orthopedic Surgeons on the Surgical Management of Anterior Cruciate Ligament Injury.

Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine·2026
Same author

Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315).

The oncologist·2026
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Aflibercept.

Kristen K Ciombor1, Jordan Berlin, Emily Chan

  • 1Division of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 28, 2013
PubMed
Summary
This summary is machine-generated.

Aflibercept combined with FOLFIRI chemotherapy improved survival for metastatic colorectal cancer patients previously treated with oxaliplatin. However, it did not improve outcomes in first-line treatment when combined with mFOLFOX6.

Related Experiment Videos

Last Updated: May 13, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic colorectal cancer (mCRC) remains a significant health challenge.
  • Anti-angiogenic therapies targeting vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) are crucial in cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of aflibercept in combination with chemotherapy for metastatic colorectal cancer.
  • To assess aflibercept's role in both second-line and first-line treatment settings.

Main Methods:

  • Phase III VELOUR trial: Aflibercept plus FOLFIRI versus placebo plus FOLFIRI in patients with previously treated mCRC.
  • Phase II AFFIRM trial: Aflibercept plus mFOLFOX6 versus placebo plus mFOLFOX6 in first-line mCRC treatment.

Main Results:

  • VELOUR trial showed statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with aflibercept plus FOLFIRI.
  • Aflibercept plus FOLFIRI was associated with a higher incidence of grade 3 or 4 adverse events.
  • AFFIRM trial did not demonstrate improved PFS or response rate with aflibercept plus mFOLFOX6 in first-line therapy.

Conclusions:

  • Aflibercept plus FOLFIRI is a viable second-line treatment option for mCRC patients previously treated with oxaliplatin, offering survival benefits.
  • The efficacy of aflibercept in first-line mCRC treatment when combined with mFOLFOX6 requires further investigation.
  • Further research is needed to define optimal strategies for incorporating aflibercept and to develop predictive biomarkers for treatment response.